2017
Crizotinib: Renal Safety Evaluation
Perazella M, Izzedine H. Crizotinib: Renal Safety Evaluation. Journal Of Onco-Nephrology 2017, 1: 49-56. DOI: 10.5301/jo-n.5000012.Peer-Reviewed Original ResearchNon-small cell lung cancerAdvanced ALK-positive non-small cell lung cancerALK-positive non-small cell lung cancerPositive non-small cell lung cancerAnaplastic lymphoma kinase-1Renal adverse effectsAcute kidney injuryAdverse renal effectsInsulin receptor tyrosine kinase familyCell lung cancerMechanism of actionKidney injuryPeripheral edemaRenal effectsElectrolyte disordersLung cancerClinical indicationsClinical trialsRenal cystsALK inhibitorsReceptor tyrosine kinase familySmall molecule inhibitorsCrizotinibClinical useAdverse effects
1995
Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels
Perazella M, McPhedran P, Kliger A, Lorber M, Levy E, Bia M. Enalapril treatment of posttransplant erythrocytosis: efficacy independent of circulating erythropoietin levels. American Journal Of Kidney Diseases 1995, 26: 495-500. PMID: 7645558, DOI: 10.1016/0272-6386(95)90496-4.Peer-Reviewed Original ResearchConceptsRed blood cell massBlood cell massErythropoietin levelsEnalapril therapyPosttransplant erythrocytosisHemoglobin concentrationMU/mLElevated red blood cell massMean reticulocyte countRed blood cell destructionRenal transplant patientsMean pretreatment valuePlasma volume contractionMean levelsMean hemoglobin concentrationBlood cell destructionRed blood cell productionMechanism of actionEnalapril treatmentTransplant patientsMean hematocritPretreatment valuesBlood cell productionReticulocyte countEnzyme inhibitors